Spots Global Cancer Trial Database for lazertinib
Every month we try and update this database with for lazertinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | NCT02609776 | Non-Small-Cell ... | Amivantamab Amivantamab Lazertinib Carboplatin Pemetrexed | 18 Years - | Janssen Research & Development, LLC | |
| Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | NCT05469022 | Non Small Cell ... | Neoadjuvant laz... | 19 Years - | Konkuk University Medical Center | |
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | NCT06106802 | Non-Small Cell ... | Lazertinib Tepotinib | 19 Years - | Samsung Medical Center | |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | NCT06120140 | Carcinoma, Non-... | Amivantamab Lazertinib Doxycycline Minocycline Clindamycin Chlorhexidine Noncomedogenic ... | 18 Years - | Janssen Research & Development, LLC | |
| Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC | NCT05862194 | Non-small Cell ... | Lazertinib Platinum-based ... | 18 Years - | Yuhan Corporation | |
| Impact of Lazertinib Dose Modification on Effectiveness and Safety | NCT05716672 | Non-small Cell ... | Lazertinib | 20 Years - | Pusan National University Hospital | |
| A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer | NCT05388669 | Advanced or Met... | Lazertinib Amivantamab Sub... Amivantamab Int... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Lazertinib 160mg in EGFR T790M NSCLC | NCT05701384 | Lung Cancer Sta... EGFR T790M | Lazertinib | 19 Years - | Samsung Medical Center | |
| Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | NCT05469022 | Non Small Cell ... | Neoadjuvant laz... | 19 Years - | Konkuk University Medical Center | |
| Premedication to Reduce Amivantamab Associated Infusion Related Reactions | NCT05663866 | Carcinoma, Non-... | Dexamethasone Montelukast Methotrexate Amivantamab Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | NCT05469022 | Non Small Cell ... | Neoadjuvant laz... | 19 Years - | Konkuk University Medical Center | |
| A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker | NCT06156527 | Lazertinib | Lazertinib Bevacizumab Inj... | 19 Years - | National Cancer Center, Korea | |
| A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer | NCT05388669 | Advanced or Met... | Lazertinib Amivantamab Sub... Amivantamab Int... | 18 Years - | Janssen Research & Development, LLC | |
| Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations | NCT05277701 | NSCLC | Lazertinib | 20 Years - | Yonsei University | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations | NCT05299125 | Metastatic Non-... | Amivantamab Lazertinib Pemetrexed 500 ... | 18 Years - | Latin American Cooperative Oncology Group | |
| Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer | NCT05377788 | Metastatic Lung... EGFR T790M | Lazertinib | 19 Years - | Samsung Medical Center | |
| Impact of Lazertinib Dose Modification on Effectiveness and Safety | NCT05716672 | Non-small Cell ... | Lazertinib | 20 Years - | Pusan National University Hospital | |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations | NCT05299125 | Metastatic Non-... | Amivantamab Lazertinib Pemetrexed 500 ... | 18 Years - | Latin American Cooperative Oncology Group | |
| Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy | NCT06020989 | Non Small Cell ... | Lazertinib+Peme... Lazertinib Lazertinib | 19 Years - | Yonsei University | |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | NCT05498428 | Carcinoma, Non-... | Amivantamab Lazertinib Carboplatin Pemetrexed Direct Oral Ant... Low Molecular W... | 18 Years - | Janssen Research & Development, LLC | |
| Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations | NCT05277701 | NSCLC | Lazertinib | 20 Years - | Yonsei University | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy | NCT05338619 | Non-small Cell ... EGFR Positive N... Non-squamous No... | Lazertinib | 18 Years - | Korea University Guro Hospital | |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | NCT04965090 | Metastatic Non ... Recurrent Non S... | Amivantamab Lazertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer | NCT06268210 | Non-small Cell ... | Lazertinib+Peme... Lazertinib | 20 Years - | Yonsei University | |
| Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy | NCT06020989 | Non Small Cell ... | Lazertinib+Peme... Lazertinib Lazertinib | 19 Years - | Yonsei University | |
| Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations | NCT05277701 | NSCLC | Lazertinib | 20 Years - | Yonsei University | |
| A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT04487080 | Carcinoma, Non-... | Amivantamab Osimertinib Lazertinib Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | NCT06120140 | Carcinoma, Non-... | Amivantamab Lazertinib Doxycycline Minocycline Clindamycin Chlorhexidine Noncomedogenic ... | 18 Years - | Janssen Research & Development, LLC | |
| Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | NCT05477615 | Non-small Cell ... | Lazertinib Pemetrexed Carboplatin | 20 Years - | Seoul St. Mary's Hospital | |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | NCT04965090 | Metastatic Non ... Recurrent Non S... | Amivantamab Lazertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI | NCT05601973 | Non Small Cell ... | Amivantamab Lazertinib Zirabev | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT04487080 | Carcinoma, Non-... | Amivantamab Osimertinib Lazertinib Placebo | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
